tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Diabetes'

PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology

PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology

Written by Ι Stock Market Media — June 6, 2018

PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA).  It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, ...

Read More →
0

Plandaí Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes

Plandaí Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes

Written by Ι Stock Market Media — May 18, 2017

Plandaí Biotechnology (OTCQB: PLPL) announced that it will conduct a human clinical trial to study the effectiveness of using its highly bioavailable green tea extract, Phytofare® Catechin Complex, to regulate blood glucose levels in type 2 diabetics. If the positive data that was recently published in the Journal of Human Nutrition and Dietetics is any indicator, Plandaí should expect to receive its own positive data. The two studies could complement one another, and Plandaí’s ...

Read More →
0

Plandai Biotechnology Gains Credibility with NutriBullet Deal

Plandai Biotechnology Gains Credibility with NutriBullet Deal

Written by Ι Stock Market Media — April 26, 2017

Plandaí Biotechnology (OTCQB: PLPL) expects Capital Brands, LLC, the developer, marketer, and distributor of both the wildly popular NutriBullet and NutriBullet SuperFoods, to launch its reformulated product, SuperFood Fat Burning Boost®, next month. SuperFood Fat Burning Boost® is being reformulated to include Plandaí’s Phytofare® Catechin Complex. This is a landmark moment for a company like Plandaí Biotechnology that has just recently moved from solely a research and development company to focusing more on sales and ...

Read More →
0

As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection

As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection

Written by Ι Stock Market Media — July 19, 2016

Worldwide the number of people living with diabetes has reached 422 million, and if the current trend continues, over 700 million people are expected to be living with diabetes by 2025. Diabetes has clearly become a healthcare crisis on a global scale, and PharmaCyte Biotech (OTCQB: PMCB) recently received some good news in the form of patent protection that will help the company do its part in bringing a treatment to tens of ...

Read More →
0

Johnson & Johnson and Big Pharma Could Find a Diabetes “Cure” with PharmaCyte Biotech’s Type 1 Diabetes Treatment

Johnson & Johnson and Big Pharma Could Find a Diabetes “Cure” with PharmaCyte Biotech’s Type 1 Diabetes Treatment

Written by Ι Stock Market Media — February 8, 2016

Johnson & Johnson, like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, Johnson & Johnson’s head of global innovation, said that his company’s recent decision to partner with a privately held San Diego biotech was to “hedge our bets to make sure we would win in this space.” Johnson & Johnson’s deal with ViaCyte, Inc. is an effort to ...

Read More →
0

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

SILVER SPRING, Md., Jan. 06, 2016 — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 ...

Read More →
0
Page 1 of 7 12345...»
ContactUs.com